 |
Valerianna Amorosa, M.D. |
HIV; Hepatitis C; tropical/travel medicine; graft/device-associated infections |
 |
Sita Awasthi, Ph.D. |
herpes viruses, vaccine, immune evasion, complement, glycoprotein C, glycoprotein D, Us9 and glycoprotein I |
 |
Todd D. Barton, M.D. |
Medical education; infections in solid organ or bone marrow transplant recipients |
 |
Gregory P. Bisson, M.D., M.S.C.E. |
HIV outcomes and opportunistic infections, HAART |
 |
Emily Blumberg, M.D. |
Infectious disease complications of solid organ transplantation |
 |
Patrick J. Brennan, M.D. |
Nosocomial infections; tuberculosis; public reporting of healthcare associated infections; patient safety and public policy |
 |
R. Michael Buckley, M.D. |
Infections related to surgery, fevers of unknown origin, general infectious disease |
 |
Laurence U. Buxbaum, M.D., Ph.D. |
Immunology, immunoparasitology; Leishmania; parasite; IL-10; Fcgamma R; cysteine proteinase |
 |
Paul Edelstein, M.D. |
Legionnaires disease; molecular pathogenesis of bacterial infections; pneumonia; antimicrobial chemotherapy |
 |
Neil Fishman, M.D. |
Outcome assessment and quality management issues in infectious diseases |
 |
Ian Frank, M.D. |
Listeria monocytogenes; vaccines; antiretroviral therapy to treat HIV |
 |
Harvey M. Friedman, M.D.
(Division Chief) |
HSV pathogenesis; immune evasion; HSV vaccines |
 |
Leanne Gasink, M.D., M.S.C.E. |
Healthcare epidemiology; hospital acquired infections; solid organ transplantation |
 |
Stephen Gluckman, M.D. |
Parasitology; tropical medicine; HIV |
 |
Phillip Green, M.D. |
Antiretroviral therapy |
 |
Robert Gross, M.D., M.S.C.E. |
Antiretroviral therapy; HIV health services research; HIV pharmacoepidemiology |
 |
Janet Hines, M.D. |
Primary care for HIV-infected patients |
 |
Stuart Isaacs, M.D. |
Vaccinia virus; poxviruses; recombinant vaccines; next generation smallpox vaccines; counter-bioterrorism |
 |
Jay R. Kostman, M.D. |
Antiretroviral therapy; complications of HIV infection; comprehensive management of viral hepatitis |
 |
Ebbing Lautenbach, M.D., M.P.H., M.S.C.E. |
Antimicrobial resistance; healthcare epidemiology; pharmacoepidemiology; public health |
 |
Darren Linkin, M.D., M.S.C.E. |
Antimicrobial prescribing; antimicrobial resistance; hospital infection control |
 |
Vincent Lo Re III, M.D., M.S.C.E. |
HIV/viral hepatitis B and C coinfection |
 |
Rob Roy MacGregor, M.D. |
TB, osteomyelitis, HIV infection |
 |
Richard Maniglia, M.D. |
Nosocomially acquired infections and HIV |
 |
Joel Maslow, M.D., Ph.D. |
Fluoroquinolone resistance in E coli; Mycobacterium avium; mycobacterial infections |
 |
Carol McLaughlin, M.D., M.P.H. |
HIV, tropical medicine and immigrant health, maternal and child health, community-based interventions |
 |
Anne Norris, M.D. |
Dermatologic diseases in HIV; mycobacterial infections |
 |
Judith O'Donnell, M.D. |
Healthcare epidemiology and hospital-acquired infections, sexually-transmitted infections including syphilis, C. difficile infection, and mycobacterial infections |
 |
Steven Reiner, M.D. |
Lymphocyte differentiation and the host response to parasitic disease |
 |
Harvey Rubin, M.D., Ph.D. |
Mycobacterium tuberculosis; cell biology of serine proteases and protease inhibitors; Biomolecular Computation |
 |
Mindy Schuster, M.D. |
Infectious complications of cancer chemotherapy and bone marrow/stem cell transplantation; treament and prevention of invasive fungal infections in immunosuppressed hosts |
 |
Karen Sims, M.D., Ph.D. |
Infections in solid organ transplant patients |
 |
Pablo Tebas, M.D. |
Treatment of HIV infection and the study of the metabolic complications associated with HIV infection and its treatment; ACTU |
 |
Drew Weissman, M.D., Ph.D. |
Dendritic cell, RNA innate immunity, RNAi, HIV vaccine, RNA gene therapy |
